Hpv chimeric particle

FIELD: biotechnology.

SUBSTANCE: chimeric virus-like particle (VLP) of human papilloma virus (HPV), and method for its production and extraction, methods for prevention or treatment of HPV infection or cervical cancer, and for induction of an immune response in the patient, including the administration of proposed HPV VLP, as well as the application of the proposed HPV VLP in these methods and in production of pharmaceuticals to implement these methods, are proposed. The proposed chimeric HPV VLPS has a diameter of about 30 nm and contains a chimeric polypeptide HPV 16 L1/L2, which consists of a polypeptide HPV 16 L1, in which the peptide HPV 16 L2 from the amino acid residue 414 is inserted. The peptide contains from 13 to 26 amino acids. The amino acids of the inserted HPV 16 L2 peptide replace the corresponding amino acids of the HPV 16 L1 polypeptide. A method is also provided for the production of said HPV VLP in a plant in which successful assembly of small chimeric HPV VLPs, having a diameter of 30 nm, takes place.

EFFECT: proposed group of inventions can be used in medicine for the prevention or treatment of HPV infection or in antitumor therapy for cervical cancer.

28 cl, 32 dwg, 11 tbl, 3 ex



Same patents:

FIELD: medicine.

SUBSTANCE: claimed invention relates to the field of biotechnology and deals with a method of detecting a provirus of cattle leukosis. The characterised method includes the detection of LTR (Long Terminal Repeat) fragment - a sequence of the leukosis provirus. Determination of the size of an amplified fragment of a nucleotide sequence by the electrophoretic separation in an agarous gel is performed. As primers applied are oligonucleotides: BL1.F 5-GAGTTAGCGGCACCAGAAGC-3 and BL1.R 5-ATAGAGCTCGCGGTGGTCTC-3. The product of synthesis constitutes 175 pairs of the nucleotides. A genomic DNA is extracted by a sorbent method with the following elution in TE buffer, amplification is carried out in the mode: 95°C for 3 minutes 1 time, 94°C for 20 seconds - denaturation, 66°C for 20 seconds - annealing of the primers, 74°C for 25 seconds - elongation, 45 times, 74°C for 3 minutes - chains completion. As a positive control of reaction proceeding applied is a preparation of a positive control of BLV antigen.

EFFECT: invention can be applied in the molecular-genetic diagnostics of animal diseases and scientific research in veterinary.

2 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: inventions concern the influenza virus strains A/PR/8/59/M2 (H1N1), A/California/1/66 (H2N2) and A/Tokyo/3/67 (H2N2). The vaccinal strains A/59/M2/California/66/2211 (H2N2) and A/59/M2/Tokyo/67/22111 (H2N2) are reassortants prepared by crossing epidemic viruses A/California/1/66 (H2N2) and A/Tokyo/3/67 (H2N2) with cold-adapted heat-sensitive virus A/PR/8/59/M2 (H1N1). The strains A/59/M2/California/66/2211 (H2N2) and A/59/M2/Tokyo/67/22111 (H2N2) are characterised by heat sensitivity, cold adaption, safety and immunogenicity for laboratory animals. The reassortants has inherited two genes coding surface virus antigens (hemagglutinin and neuraminidase) from the epidemic virus and the rest six genes coding non-glycated proteins, from the attenuation donor A/PR/8/59/M2 (H1N1).

EFFECT: presented inventions can be used in preparing a live influenza intranasal vaccine for adults and children.

3 cl, 2 dwg, 4 tbl, 1 ex

FIELD: biotechnology.

SUBSTANCE: proposed primers comprise endonuclease cleavage sites, flanking genomic regions encoding the glycoproteins Gn and Gc, and the nucleoprotein N, for obtaining libraries of genes encoding glycoproteins Gn and Gc and N nucleoprotein of Rift Valley fever virus.

EFFECT: invention can be used in creating a bank of nucleotide sequences encoding immunodominant proteins of Rift Valley fever virus Gn, Gc and N, which can be used for creation of diagnostic and vaccine preparations based on recombinant technologies.

3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the field of biotechnology and can be used for the identification of heteromultimeric ubiquitins possessing an ability to bind with a ligand-antigen. The method includes the contact of a totality of heterodimeric modified ubiquitins, including two ubiquitin monomers, bound to each other by a head-to-tail scheme, with the potential ligand in a display way. Each of the said monomers is modified in a different way and contains 5-8 substitutions in positions 2, 4, 6, 8, 62, 63, 64, 65, 66 and 68 SEQ ID NO:1. After that, a heterodimeric modified protein, which has bound with the ligand with the binding affinity Kd in the range of 10-7-10-12 M and the monovalent binding activity. Claimed are DNA-libraries, responsible for obtaining a population of the said heteromultimeric ubiquitins, as well as libraries of proteins, obtained by the expression of the said DNA-libraries.

EFFECT: invention makes it possible to obtain the novel bonding proteins based on heteromultimeric ubiquitin, capable of specific high affinity binding with the selected ligands.

8 cl, 17 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented a composition and a method for producing it. The characterised composition contains: an effective amount of a viral antigen, which represents a live attenuated rotavirus pre-processed in 0.1% human serum albumin, and a pharmaceutically acceptable buffer. A method for producing a composition involves growing Vero cell culture pre-cultured in the presence of 5% foetal calf serum and 0.1% human serum albumin, infecting the above Vero cell culture with the live attenuated rotavirus, propagating the virus in the cell culture and adding a pharmaceutically acceptable buffer to the above virus.

EFFECT: presented inventions can be used to prevent rotavirus infection and/or rotavirus gastroenteritis.

11 cl, 17 dwg, 4 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: inventions deal with infectious molecule of nucleic acid, coding infectious porcine Torque teNO viruses (PTTV), which contains at least one copy of genome sequence, selected from the group, consisting of sequences, corresponding to genotypes or subtypesPTTV1a-VA, PTTV1b-VA, PTTV2b-VA and PTTV2c-VA, as well as to biologically functional plasmid or viral vector, containing such infectious nucleic genome sequence, and host-cell, containing such plasmid or vector. In addition claimed inventions include live, attenuated expressible with vector application and purified recombinant capsid subunit or killed viral vaccines for protection against PTTV infection, as well as methods of immunisation of pigs against PTTV viral infection by said vaccine introduction.

EFFECT: characterised inventions can be used to prevent infection, caused by porcine Torque teNo virus.

23 cl, 53 dwg, 5 tbl, 24 ex

FIELD: biotechnology.

SUBSTANCE: characterised strain was isolated from diseased pigs and produced by serial passages on sensitive hetero- and homologous cell cultures and deposited in the collection of the FSBI "Federal Animal healthcare centre" under the registration number of FMD virus strain A No.2187/Kuti/2013 (production). The presented strain is reproduced in monolayer cell culture of porcine kidney (PK), passaged cell cultures of kidney of Siberian mountain ibex (SMIK-30), VPK-21 and IB-RS-2. During 18÷24 hours of incubation the virus yield in the said cell cultures reaches the values of 6.0÷7.0 lg TCD50/cm3. At high multiplicity of infection (1÷10 TCD/cell) causes TCID50 after 5 hours, while maintaining the original characteristics when passaging in cell cultures for 5 passages.

EFFECT: invention can be used to monitor the antigenic and immunogenic activity and for producing biological products for diagnostics and specific prophylaxis of FMD of type A.

6 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology. The subject of the invention is a new strain of the Sendai virus Sen293nsk1 adapted to effective replication in the human cell culture HEK293. The produced strain of the Sendai virus possesses lower virulence for laboratory mice and higher ability to destroy human tumour cells. The strain is supposed to be used experimentally as a therapeutic oncolytic preparation for treating malignant diseases. The invention can be used in treating oncologic diseases.

EFFECT: invention enables providing higher clinical effectiveness in oncologic diseases by using the murine Sendai virus non-pathogenic for humans, possessing an increased oncolytic activity and intensifying anti-tumour immunity.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to such compositions and pharmaceutical compositions, which include poxviruses, and namely to those, which include extracellular enveloped viruses. Claimed invention also relates to such method, which is intended for production of poxviruses, as well as poxviruses, obtained in accordance with claimed invention. In addition, claimed invention also relates to application of claimed poxviruses and said composition for medication preparation.

EFFECT: obtaining pharmaceutical compositions, which include poxviruses.

11 cl, 3 dwg

FIELD: biotechnology.

SUBSTANCE: method of detection and differentiation of a genome of the vaccine strain B-82 of the myxoma virus of rabbits from the field isolates comprises: extraction of the DNA from the biological material, posing a multiplex polymerase chain reaction using synthesised primers complementary to regions of genes M130R and M151R of the myxoma virus of rabbit, and having the following nucleotide composition: MF 5'TGG-AGC-TTT-TCA-AGC-ATT 3', MR 5'ATA-TCT-CGG-CTC-TAG-GGC-GAG 3', MZ 5' [FAM]-AG-CGT-CGG-ACG-TCT-TCG-TT-[RTQ1] 3', VF 5'AGC-CCT-ATA-AAC-CCG-TAG-ACG-AAC 3', VR 5'CAA-GCT-TTT-TTT-TAT-CCT-CGT-CCG 3', VZ 5' [R6G]-TCG-ACG-GTT-TCG-TCC-GCC-TTC-TTG-[BHQ2] 3', DNA amplification of the virus and evaluation of the reaction. The present inventions may be used in veterinary virology for the detection and differentiation of the vaccine strain B-82 of the myxoma virus of rabbits from the field isolates.

EFFECT: increase in accuracy.

2 cl, 6 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: method for synthesis of a 1,5-bis-(4-tetradecyl-1,4-diazoniabicyclo[2.2.2]octan-1-yl)pentane tetrabromide (C47H100Br4N4) derivative includes dissolving 1-tetradecyl-4-aza-1-azoniabicyclo[2.2.2]octane bromide in methanol while heating to temperature of 55°C, while stirring, adding two portions 1,5-dibromomethane to the obtained solution until a reaction mixture is obtained, which is then stirred and cooled to temperature of 18-22°C, after which 20 ml acetonitrile is added to the obtained mixture, followed by separation of the precipitate from the mother solution, wherein the precipitate is filtered out and dried in a vacuum and the obtained mother solution is evaporated to obtain a viscous syrup-like residue to which 40 ml acetonitrile is added and stirred while boiling with a reflux condenser to obtain a suspension which is then cooled to temperature of 18-22°C and the precipitate formed is filtered out, dried in a vacuum and mixed with the previously obtained precipitate to obtain the end product.

EFFECT: wider range of antiviral agents for veterinary needs and obtaining a polycationic compound which enables to deal with a wide range of infectious diseases caused by RNA viruses.

7 cl, 1 dwg, 1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to viral vaccines for the dog protection against parvovirus infection, preparing and using them. More specifically, the invention refers to an attenuated recombinant parvovirus containing a DNA sequence of type 2 first attenuated parvovirus with the DNA coding a capsid protein of the first parvovirus is substituted by a capsid protein of type 2c parvovirus. The vaccine on the basis of the above virus is able to induce higher titres of the protective antibodies against a risk of type 2c parvovirus infection, preserving at the same time a good immunity against type 2 parvovirus. The strains of the recombinant virus also have been found to remain attenuated.

EFFECT: preparing viral vaccines for the dog protection against parvovirus infection.

6 cl, 4 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to the field of biotechnology and virology. Described is a chimeric pestivirus, where the said chimeric pestivirus includes the cattle diarrhea virus, which does not express its homologous Erns protein. The said chimeric pestivirus expresses a heterologous Erns protein, originating from the other pestivirus, or a natural, synthetic or genetic version of the said heterologous Erns protein. Also described are methods and sets for treatment or prevention of propagation of the infection, caused by the cattle diarrhea virus, as well as methods for a differentiation between the vaccinated animals and the animals, infected with the virus of a wild type.

EFFECT: invention can be used as immunogenic compositions and vaccines in animal breeding.

13 cl, 4 tbl, 5 ex

FIELD: biotechnologies.

SUBSTANCE: invention proposes recombinant classical swine fever virus (1111) that contains deletion of at least one amino-acid in TAVSPTTLR domain of protein E2, which corresponds to positions 829-837 of parent polyprotein CSFV, as well as the corresponding vaccine, kDNA molecule, a protection method of an animal against CSFV and a differentiation method of CSFV-infected animals.

EFFECT: invention can be used for vaccination of animals against swine fever.

17 cl, 10 dwg, 2 tbl, 2 ex

FIELD: biotechnologies.

SUBSTANCE: nanocomposites made of nanoparticles of titanium dioxide in amorphous or crystalline (anatase, brookite) form, immobilised polylysine derivatives of oligonucleotides (PL-oligo) and photoactivated arylazide groups introduced in amino groups of polylysine. All components of the nanocomposite perform a certain function: TiO2-nanoparticles support transfection of cells; polylysine helps to immobilise oligonucleotide onto the surface of nanoparticles and adds functional groups (NH2), which make it possible to add additional reaction-capable groups; oligonucleotides of certain sequence forward the composite towards the target sections of the virus RNA; the photoactivated perfluoroarylazide group after irradiation with light may damage nucleic acids.

EFFECT: directed action at genetic material inside a cell and suppression of its further functioning.

9 cl, 3 dwg, 15 ex

FIELD: medicine.

SUBSTANCE: invention refers to molecular biology, genetic engineering and virology. What is presented is a method for producing a preparation containing the viral antigens, involving a) cell inoculation with an infectious in the fluid, b) reproduction of the above virus in the above cells, c) collection of the above reproduced virus, d) inactivation of the above collected virus, and e) treatment of the above inactivated virus with a detergent to produce the preparation containing the viral antigens.

EFFECT: method may be used in medicine and pharmacology to produce vaccines.

21 cl, 1 dwg, 2 tbl, 3 ex

FIELD: biotechnologies.

SUBSTANCE: method to determine virulent and pathogenic forms of flue viruses is based on collection of an initial sample of a tissue/physiological fluid from patients who are possibly sick with flu, extraction and treatment of RNA preparations from the initial sample, synthesis of cDNA on the RNA matrix, analysis of a nucleotide sequence of the produced cDNA with the purpose to identify the mutation status of specific positions of flu virus segments, and calculation of two scoring-factors, by the value of which they decide on extent of virulence and pathogenicity of a flu virus.

EFFECT: method may be used to determine virulent and pathogenic forms of flu virus.

5 tbl, 4 ex

FIELD: biotechnologies.

SUBSTANCE: method to produce a flu virus is proposed, according to which hens are injected with a vaccine against flu, eggs are collected from vaccinated hens, the process of embryogenesis is initiated, eggs with a developing embryo are infected, introducing a flu virus into an allantoic cavity, infected eggs with developing embryos are incubated under temperature and moisture, which provide for virus replication, and the allantoic liquid is collected, which contains a virus. Also application of the flu virus and eggs produced by this method is proposed.

EFFECT: method improvement.

26 cl, 9 tbl, 5 ex

FIELD: biotechnology.

SUBSTANCE: method of preparation of composition comprising (i) virus-like particles is described, and the said virus-like particles are virus-like particles of RNA-containing bacteriophage, and (ii) an oligonucleotide, and the said oligonucleotide is packaged in the said virus-like particles. Also a method of production of nucleotide composition comprising oligonucleotides used in the above mentioned methods is described. Also the nucleotide composition produced with the method of this invention and their application is described. The said composition preferably has a purity of at least 98%, most preferably at least 99%. The invention can be used in medicine.

EFFECT: increased purification.

25 cl, 6 dwg, 1 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: what is presented is an influenza A virus propagation inhibitor; the inhibitor represents a complex of titanium dioxide nanoparticles and virus-specific deoxyribozyme. Deoxyribozyme is presented by an oligonucleotide of the following nucleotide sequence - 5'-GAAATAAGAGGCTAGCTACAACGACCTTCATTA.

EFFECT: invention may be used for influenza A virus propagation inhibition in infected eukaryotic cells.

3 cl, 6 dwg, 1 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the field of biotechnology and can be applied for the selection of affine molecules. Constructed is a plasmid DNA pGST/APT/X 6193 bp long, with the weight of 4.09 MDa, containing as a genetic marker the gene β-lactase and unique sites of the recognition of restriction endonucleases, located at the following distance to the right from the site NdeI: BgIII 665bp, BamHI 779 bp., XhoI 801 bp. The plasmid pGST/APT/X consists of a NdeI-XhoI DNA fragment of the commercial plasmid pET22b(+) and nucleotide sequence SEQ ID NO:1, inserted by sites NdeI-XhoI and combining in its composition the sequences, which code a fragment of a gene of glutathione-S-transferase, a peptide substrate of a lethal factor of anthrax RRKKVYPYPME, peptide GGLNDIFEAQKIEWHED, biotinylated in vivo under the influence of E.coli biotin-ligase, and a linker sequence, substituted by genetic-engineering manipulations by sites of restriction endonucleases BamHI and XhoI for a sequence, coding a target protein B-subunit of shiga-toxin I.

EFFECT: invention makes it possible to carry out the selection of highly specific aptamers to the said target protein.

2 cl, 4 dwg, 4 ex